Day: February 5, 2025

TORONTO, Feb. 05, 2025 (GLOBE NEWSWIRE) — AGF Management Limited reported total assets under management (AUM) and fee-earning assets1 of $54.4 billion as at January 31, 2025.AUM($ billions) January 31,2025   December 31,2024   % ChangeMonth-Over-Month   January 31,2024   % ChangeYear-Over-Year  Total Mutual Fund $31.4   $30.1     $25.1    Exchange-traded funds + Separately managed accounts $2.7   $2.8     $1.6    Segregated accounts and Sub-advisory $6.8   $6.4     $7.0    AGF Private Wealth $8.6   $8.4     $7.7    Subtotal (before AGF Capital Partners AUM and fee-earning assets1) $49.5   $47.7     $41.4    AGF Capital Partners $2.8   $2.8     $0.1    Total AUM $52.3   $50.5   3.6 % $41.5   26.0 %AGF Capital Partners fee-earning assets1 $2.1   $2.1     $2.0    Total AUM and fee-earning assets1 $54.4   $52.6   3.4 % $43.5   25.1 %           Average...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. “This manuscript provides comprehensive data on the safety and efficacy of Bizengri® and demonstrates the meaningful results observed in the eNRGy...

Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32 Fiscal 2025 outlook updatedDUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%. “We are pleased with our results through the first nine months of the fiscal year,” said Dan Carestio, President and CEO of STERIS. “We are...

STAMFORD, Conn., Feb. 05, 2025 (GLOBE NEWSWIRE) — Star Group, L.P. (the “Company” or “Star”) (NYSE:SGU), a home energy distributor and services provider, today announced financial results for its fiscal 2025 first quarter, the three month period ended December 31, 2024. Three Months Ended December 31, 2024 Compared to the Three Months Ended December 31, 2023For the fiscal 2025 first quarter, Star reported a 7.6 percent decrease in total revenue to $488.1 million compared with $528.1 million in the prior-year period, reflecting lower average petroleum prices even as product volumes rose slightly year-over-year and service and installation revenue increased. The volume of home heating oil and propane sold during the fiscal 2025 first quarter rose by 2.3 million gallons, or 2.8 percent, to 82.4 million gallons,...

Further to the Company’s Recent Announcement, Beyond Oil Reports the Successful Delivery of its First Order; Beyond Oil received January’s payment under the previously announced Agreement which includes minimum commitments of US$8.3M for 2025 VANCOUVER, B.C., KIBBUTZ YIFAT, Israel, and NEW YORK, NY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has successfully delivered the first order under its previously announced Master Distribution Agreement with Latitude Ltd. (“Latitude”). The first shipment, totaling 10.8 tonnes (T) of the Beyond Oil...